Patents by Inventor Daiqing Liao

Daiqing Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLYPEPTIDE INHIBITOR OF DE NOVO LIPOGENESIS IN CANCER CELLS
    Publication number: 20240066094
    Abstract: Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.
    Type: Application
    Filed: September 26, 2023
    Publication date: February 29, 2024
    Inventors: Daiqing Liao, Iqbal Mahmud, Guimei Tian
  • HDAC inhibitor compounds and methods of treatment
    Patent number: 11731934
    Abstract: The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: August 22, 2023
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Daiqing Liao, William R. Roush, Ryan L. Stowe
  • BENZOYLHYDRAZIDE-DERIVED HDAC DEGRADERS AS THERAPEUTICS FOR TREATING CANCER AND OTHER HUMAN DISEASES
    Publication number: 20230181746
    Abstract: In one aspect, the disclosure relates to benzoylhydrazide-derived PROTACs that are highly effective at degrading HDAC3 and that are also capable of targeting, to a lesser extent, other HDAC isoforms, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers including hematologic cancers, breast cancer, other malignancies, and other serious diseases involving aberrant HDAC activity using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Application
    Filed: May 17, 2021
    Publication date: June 15, 2023
    Inventors: Daiqing LIAO, Yufeng XIAO, Xuan ZHANG, Guangrong ZHENG
  • POLYPEPTIDE INHIBITOR OF DE NOVO LIPOGENESIS IN CANCER CELLS
    Publication number: 20210113649
    Abstract: Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.
    Type: Application
    Filed: April 5, 2019
    Publication date: April 22, 2021
    Inventors: Daiqing Liao, Iqbal Mahmud, Guimei Tian
  • HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT
    Publication number: 20210009509
    Abstract: The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
    Type: Application
    Filed: August 21, 2020
    Publication date: January 14, 2021
    Inventors: Daiqing LIAO, William R. ROUSH, Ryan L. STOWE
  • HDAC inhibitor compounds and methods of treatment
    Patent number: 10807944
    Abstract: The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: October 20, 2020
    Assignees: University of Florida Research Foundation, Inc., The Scripps Research Institute
    Inventors: Daiqing Liao, William R. Roush, Ryan L. Stowe
  • HDAC INHIBITOR COMPOUNDS AND METHODS OF TREATMENT
    Publication number: 20170174619
    Abstract: The instant invention describes hydrazide-containing compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
    Type: Application
    Filed: March 30, 2015
    Publication date: June 22, 2017
    Inventors: Daiqing Liao, William R. Roush, Ryan L Stowe